Nauset Wealth Management’s AbbVie ABBV Stock Holding History

Nauset Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$107K	Buy	+657	New	+$95.4K	0.09%	80

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Nauset Wealth Management's ABBV Position: Q1 2022 in Review

Nauset Wealth Management opened a new position in AbbVie (ABBV) in Q1 2022: 657 shares worth $107K. The stake represents 0.09% of the portfolio and ranks #80 among its holdings.

3,051 funds tracked by Wall St. Rank hold ABBV as of Q1 2022.

Nauset Wealth Management held 657 shares of AbbVie worth $107K as of Q1 2022.
AbbVie was a new Nauset Wealth Management position in Q1 2022.
AbbVie made up 0.09% of Nauset Wealth Management's portfolio in Q1 2022, its #80 holding.
3,051 funds tracked by Wall St. Rank held AbbVie as of Q1 2022.

Based on Nauset Wealth Management's 13F filing for Q1 2022, filed 28 Apr 2022.